Triple negative breast cancer (TNBC) is a highly recurrent malignancy, but still lacks effective targeted therapy. Fortunately, ipatasertib, an oral AKT inhibitor under development, have shown potential as a future targeted therapy treatment option for TNBC treatment. The preliminary results were reported in the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting. The researchers conducted a double-blind, placebo-controlled, randomized phase II LOTUS trial that recruits patients with treatment naïve TNBC to compare the efficacy of ipatasertib with placebo. The results showed that the objective response rate (ORR) was 40 % in the ipatasertib group and 32% in the placebo group. For patients carrying PIK3CA/AKT/PTEN gene mutations, the ipatasertib group showed better response than the placebo group (9 % vs 4.9 %) in the subgroup analysis. Furthermore, medium progression-free survival (PFS) was 6.2 and 4.9 months in the ipatasertib and placebo group, respectively (HR=0.60). Patients harboring PIK3CA/AKT/PTEN gene mutations showed prolonged medium PFS in the ipatasertib group compared to the placebo group (9 and 4.9 months, respectively, HR=0.44). Though the results of the study still require further investigation in the phase III trial, ipatasertib nevertheless may become one of the targeted therapy development options for TNBC treatment.